Key result
Two hybridoma colonies successfully produced IgG1 kappa monoclonal antibodies that specifically neutralized Poliovirus Type 2 without cross-reactivity to types 1 and 3.
Why the study?
Poliovirus remains a major public health problem in developing countries, and production of monoclonal antibodies against Poliovirus Type 2 is needed to prepare for and respond to its re-emergence.
Answers are grounded in this paper and cite their sources.
The produced monoclonal antibodies against Poliovirus Type 2 demonstrate high specificity and neutralizing capability, making them valuable tools for polio research, diagnosis, and vaccine quality control.
Monoclonal Antibodies (mAbs) are used for biomedical research, diagnosis, treatment, production, and the quality control of biological products. mAbs are also very helpful in poliovirus research studies because it is still one of the major public health problems in developing countries. The main objective of this study was the production of mAbs against Poliovirus Type 2 (PV2) to be prepared and respond to the re-emergence of this virus. After fusion of immunized B cells prepared from mice with myeloma tumor cells and screening of about 250 hybridoma colonies, 22 with the highest antibody titer and without cross-reaction with others types were selected and cloned by limiting dilution. In the end, two colonies capable of secreting mAbs against epitopes of PV2 were used to produce mAbs. The mAbs were characterized by antibody assays, isotyping, and epitopes analysis using western blotting test, the crossreactivity with other types, as well as stability, sterility, and mycoplasma tests. The results indicated that the produced mAbs had high specificity, sensitivity and stability against PV2 without any cross-reactivity and were of IgG1 Kappa chain with similar bands at 26 kDa during electrophoresis associated with viral protein VP3 neutralization. These mAbs were specific in serum neutralization tests for PV2 vaccine strain, and therefore, they are potentially valuable for routine polio research, diagnosis, isolation, production, and control of poliovirus vaccines.
No takes yet. Share an insight, caveat, or question.
Kamalzadeh et al. (2019) studied Poliovirus Type 2. Monoclonal antibody against Poliovirus Type 2 was evaluated on Production and characterization of neutralizing mAbs against PV2. Two hybridoma colonies successfully produced IgG1 kappa monoclonal antibodies that specifically neutralized Poliovirus Type 2 without cross-reactivity to types 1 and 3.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: